Core for Life - a new European alliance in biomedical research: http://t.co/Hvv6P88kRt
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
FORMAC Pharmaceuticals N.V., a Belgian-based drug delivery and development company, today announced that Filip Kiekens will become the company’s new Chief Scientific Officer and that Laurent Schueller will become the company’s new Chief Operating Officer.
Dr. Filip Kiekens joins FORMAC from the Pharmaceutical Development Division of Johnson & Johnson (JANSSEN Pharmaceutica NV), where he led early and late development projects with increasing responsibilities. During his extensive research and development of complex active compounds, he was recognized with the JNJ Standards of Leadership award and the Philip B. Hofmann Research Scientist Award. For the successful development of INTELENCE®, a novel HIV drug, he was awarded the Johnson Medal, the most prestigious award given to scientists and technologists in Johnson & Johnson. As one of the Flanders District of Creativity Fellows, Filip merges his scientific passion of formulating complex molecules with his entrepreneurial spirit into business opportunities.
Jan Rosier, CEO of FORMAC Pharmaceuticals, says: “We are extremely pleased to have Filip in our team because of his expertise in solving drug delivery problems for insoluble drugs. In particular his expertise in solid dispersion technologies and his know-how in introducing these technologies in full scale manufacturing settings is of particular importance for FORMAC”.
Filip graduated as a pharmacist in 1995 and holds a Ph.D. in Pharmaceutical Technology from the University of Ghent, Belgium.
Dr. Laurent Schueller joins FORMAC Pharmaceuticals N.V. from Tibotec, where he was Chemical & Pharmaceutical Team Leader for the development of 2 late stage programs for the treatment of tuberculosis (TMC207) and HIV (TMC114). He was also involved in defining outsourcing strategies for the pharmaceutical development projects of Johnson and Johnson. Prior to his responsibilities in drug development, Laurent was responsible for budget management & control of a diverse portfolio of early and late development drugs. At FORMAC, Laurent will be responsible for the drug development programs and the associated operational activities.
Laurent graduated as a Pharmacist from the University of Strasbourg, France and holds a Ph.D. in Pharmaceutical Technology from the University of London, UK. He obtained his MBA from the Vlerick Business School in Belgium.
Source: FORMAC Pharmaceuticals